Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Pharmaceutical Contract Manufacturing (CMO) Market – Growth, Trends and Forecasts (2019 – 2024)
| Packaging | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Packaging
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The Pharmaceutical Contract Manufacturing (CMO) Market is expected to register a CAGR of over 7.75% during the forecast period 2019 – 2024. The growing demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing. Additionally, pharmaceutical companies have been directing their priorities toward the core areas of competency, and hence, prefer not to dispense available resources, expertise, and technology on formulating the final dose of medicines.
In order to adapt to the paradigm shift in the biotechnology industry and the present biopharmaceutical industry trends, CMOs have decided to move away from solely renting manufacturing units to a business model that offers extensive development and production support.
CMOs and contract development and manufacturing organizations (CDMO) individually or together have started offering many specialized, value-added services for customers with early-stage development needs and for those who require support to generate a biologics license application (BLA) enabling process validation data package.
CMOs have begun offering early development support to their customers, along with fully integrated services, which include specialized services like aseptic fill–finish. Though the concept of CDMO was introduced earlier, it has been fully realized over the last few years.
The costs invested in R&D are continuously increasing, and yet the useful results returned from these processes are becoming rarer. Many companies have realized that moving this part of the business overseas and taking advantage of the still-emerging pharmaceutical markets is an effective method of cutting costs.
Despite the existing evidence regarding cost savings and competences that can be accrued, many companies are reluctant to give up that control, going so far as to state that logistics are a core competency for the company. However, that scenario seems to be changing slowly.
Scope of the Report
A contract manufacturing organization (CMO), called a contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing
Key Market Trends
Active Pharmaceutical Ingredient (Api) Manufacturing is expected to register a Significant Growth
The demand for API manufacturing has witnessed a sustained rise in the past few years, and it is expected to continue growing steadily, with further patent expiries expected in the future and a subsequent increase in global generic production capacities. Most of the companies in this industry are increasingly focusing on the development of biological APIs, which is driving the API market. The general prescription drug sub-segment occupies a major share in the API manufacturing segment, as compared to OTC drugs.
Other factors driving the growth of the API segment includes stringent government initiatives in the healthcare sector, innovation in biologics, and rise in the incidence of cancer and age-related diseases. However, strict European regulatory policies may hinder the segment’s growth.
Captive manufacturers are currently leading the API market; however, they are slowly expected to lose their market share to contract manufacturers toward the end of the forecast period. This is due to the complex and expensive in-house manufacturing of API and increasing competition from emerging players in this industry.The increasing emphasis on high-potency APIs is driving the growth of the segment. The novel technologies for HPAPIs can potentially change the in-out balance of CMOs in this fast-growing segment.
As the big pharma companies continue to scale down on manufacturing, greater opportunities for the CMOs are expected, both in the biopharmaceutical and small molecule API segments.
North America is Expected to Hold Major Share in United States
In North America especially, the United States is the world’s largest market for drugs and accounts for almost half of the R&D spending in pharmaceutical and biotechnology markets. Hence, CMOs play a critical role in this market and have invested in new facilities and technologies to cater to a wide range of outsourcers.The United States is expected to face strong competition from Asia-Pacific CMO providers, especially in solid dose formation.
The consolidation of CMOs is expected to occur within the next five years, as the competitors will either leave the industry, or abandon a specific area within the industry, or go out of business. This improves the pricing power of value-added CMOs.
Companies, such as Catalent and Patheon, have an established customer base in the United States and are leaders in oral and sterile dose formulations. These companies have been aggressive in expanding their products/services/capabilities through strategic alliances. With the recent acquisition of Confab, DPT Laboratories has become the global leader in prescription semi-solid and liquid formulations, acquiring proprietary products.
Competitive Landscape
The pharmaceutical contract manufacturing market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability.
The companies operating in the market are also acquiring start-ups working on enterprise network equipment technologies to strengthen their product capabilities. In April 2017, Famar announced the closure of the acquisition of a manufacturing site from Bayer, located at Pointe-Claire, Canada, with the transfer of full ownership of the plant to Famar.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Increasing Outsourcing Volume By Big Pharmaceutical Companies
4.3.2 Expansion In The Service Offering Of CMOS
4.3.3 Advent Of CDMO Model Into The Market
4.3.4 Increasing Investments In R&D
4.4 Market Restraints
4.4.1 Increasing Lead Time & Logistics Costs
4.4.2 Stringent Regulatory Requirements
4.4.3 Capacity Utilisation Issues Affecting The Profitability Of Cmos
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
4.7 Technology Snapshot
4.7.1 Dosage Formulation Technologies
4.7.2 Dosage Forms by Route of Administration
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
5.1.2 Finished Dosage Formulation (FDF) Development & Manufacturing
5.1.3 Secondary Packaging
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 Rest of Asia-Pacific
5.2.4 Latin America
5.2.4.1 Brazil
5.2.4.2 Argentina
5.2.4.3 Mexico
5.2.4.4 Rest of Latin America
5.2.5 Middle East and Africa
5.2.5.1 UAE
5.2.5.2 Saudi Arabia
5.2.5.3 South Africa
5.2.5.4 Nigeria
5.2.5.5 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Baxter BioPharma solutions
6.1.3 Boehringer Ingelheim International GmbH.
6.1.4 Jubilant Life Sciences Limited
6.1.5 Recipharm AB
6.1.6 Catalent Inc.
6.1.7 Recipharm AB
6.1.8 Patheon Inc
6.1.9 Famar S.A.
6.1.10 Aenova Group
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development & Manufacturing
Secondary Packaging
Geography
North America
US
Canada
Europe
Germany
UK
France
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
Rest of Asia-Pacific
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Middle East and Africa
UAE
Saudi Arabia
South Africa
Nigeria
Rest of Middle East and Africa
Robotics Market – Growth, Trends, and Forecast (2019 – 2024)
| Automation | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Automation
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The Robotics Market was valued at USD 31.78 billion in 2018 and is expected to register a CAGR of 25% over the forecast period of 2019-2024. In the past decade, industrial robots used to be high priced, due to which, the ROI is expected to be achieved after a decade. However, presently, smaller collaborative robots are priced for companies to receive ROI in months, instead of decades, often costing around USD 20,000. Declining sensor prices and increasing adoption have further aided lower costs.
The market studied is experiencing a significant transformation, with robots growing beyond being the workhorses of industrial shop floors and beginning to adopt the roles of personal assistants, surgical assistants, delivery vehicles, autonomous vehicles, exoskeletons, and unmanned aerial vehicles, among many other uses.
Apart from the affordability and user experience, size and shape also plays an essential role in driving the robotics industry. The demand for industrial robots has accelerated since 2010, considerably, due to the ongoing trend toward automation and continued innovative technical improvements in industrial robots.
The market is further expanding into new territories, with small- and medium-sized industries adopting automation, thereby creating demand for robots. The availability of small-capacity and cost-effective solutions from major providers is enabling the penetration of robots into industries.
Scope of the Report
The global robotics market is segmented by type, end user, and region. By type of robots, the market studied is segmented into industrial robots and service robots. Industrial robots are majorly used in the manufacturing industries. Service robots assist human beings, typically by performing tasks. The types of service robots considered in the scope are professional and personal robots. Further, these robots cater to specific applications in particular industries. For instance, industrial robots serve well in the automotive, food and beverage, electronics, metals and mining, plastic and chemical industries. Service robots are used for logistics, military and defense, healthcare, public relations, exoskeletons, construction, household, entertainment, and agriculture. Software solutions offered by vendors, for operating or gathering data from robotic systems, are not considered in the scope of the study.
Key Market Trends
Service Robotics to Register Highest Growth
Factors like the aging population and shortages of healthcare workers is driving the demand for assistive technology robots. Companies like KUKA(healthcare subsidiary Swisslog) are specializing in robots for healthcare applications. For instance, Swisslog’s Relay is designed for inpatient and outpatient services, like the transport of medicines and other hazardous medications, including chemotherapy.
The emergence of robotic technology has transformed the way businesses are carrying out their operations. Moreover, with the proliferation of e-commerce, the need for automated warehouses is increasing. Kiva and Mobile industrial Robots(MiR) are prominent companies among other startups that are innovating in the warehouse robotics space.
Fully automated solutions are providing huge opportunities for warehouse purposes. For instance, MiR’s warehouse robot, MiR 500, a flexible- easy-to-program robots equipped with a laser-scanning technology and lifting capacity of 1,102 lbs and a speed of about 4.5 mph, is designed to automate the transportation of pallets and heavy loads throughout a warehouse. New innovations apart from the laser technologies in warehouse robotics are being led by the startups. For instance, inVia Robotics, a California based startup is developing warehouse cobots, that can work right alongside humans.
Asia-Pacific to Hold Major Share
Asia-Pacific is expected to record the highest growth rate over the forecast period, owing to significant adoption of industrial robots throughout the region. China is dominating the regional adoption rate of robotics, owing to the massive deployment in the country’s dominating electronic and automotive manufacturing sector. As these sectors are also developing at a high rate in other economies in the region like India, there is vast potential for growth in the market studied. The regional government is also a major factor for the development of the regional robotics market. For instance, India plans to invest in military robotics, and by 2023, the country is preparing to deploy advanced robotic soldiers. Also, a New Delhi-based company is building robots for the Indian Army.
Competitive Landscape
The robotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. In Jun 2018, ABB Ltd launched the third-generation IRB 6790 foundry prime robot, at Automatica 2018, in Munich. The product is aimed at high-pressure water jet cleaning applications in harsh industrial environments. This robot increases reliability and system uptime while reducing the maintenance costs by up to 60%. In Sep 2018, Denso Corporation announced that the company agreed with Pioneer Corporation to take the stake in Tohoku Pioneer EG Corporation (Tohoku Pioneer EG), which is involved in the factory automation (FA) business and is owned by Tohoku Pioneer Corporation, a consolidated subsidiary of Pioneer Corporation.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Advent Of Industry 4.0 Driving Automation
4.3.2 Increasing Emphasis On Safety
4.3.3 Demand From The Oil And Gas Industry
4.4 Market Restraints
4.4.1 High Cost Of Installation
4.5 Industry Value Chain Analysis
4.6 Industry Attractiveness Porter’s Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Industrial
5.1.2 Service
5.2 By End User
5.2.1 End Users of Industrial Robots
5.2.1.1 Automotive
5.2.1.2 Food and Beverage
5.2.1.3 Electronics
5.2.1.4 Other End Users of Industrial Robots
5.2.2 End Users of Service Robots
5.2.2.1 Logistics
5.2.2.2 Military and Defense
5.2.2.3 Medical and Healthcare
5.2.2.4 Other End Users of Service Robots
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia Pacific
5.3.4 Latin America
5.3.5 Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ABB Ltd
6.1.2 Yaskawa Electric Corporation
6.1.3 Denso Corporation
6.1.4 Fanuc Corporation
6.1.5 Kuka AG
6.1.6 Kawasaki Heavy Industries Ltd
6.1.7 Toshiba Corporation
6.1.8 Panasonic Corporation
6.1.9 Staubli International AG
6.1.10 Nachi Robotic Systems Inc.
6.1.11 Yamaha Motor Co. Ltd
6.1.12 Seiko Epson Corporation
6.1.13 Comau SpA
6.1.14 Adept Technologies Inc.
6.1.15 Intuitive Surgical Inc.
6.1.16 Stryker Corporation
6.1.17 Maxar Technologies Ltd (Mda Corporation)
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Industrial
Service
By End User
End Users of Industrial Robots
Automotive
Food and Beverage
Electronics
Other End Users of Industrial Robots
End Users of Service Robots
Logistics
Military and Defense
Medical and Healthcare
Other End Users of Service Robots
Geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2019-2024), with a CAGR of 14.5%, mainly as a result of new drug launches.
Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe.
Europe’s expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal.
In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
The European region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in the United Kingdom.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Burden of Diabetes in the European Region
As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
Germany to Dominate the Europe GLP-1 Market
Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all the regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly over the forecast period, because of Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Telecom Towers Market – Growth, Trends and Forecast (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The Telecom Tower Market is expected to register a CAGR of over 4.56% during the forecast period 2019 – 2024. The leasing concept has enabled the MNOs to invest heavily in developing their infrastructure and reach across rural regions, thus bringing new revenues to the tower operators, through tower installations. Tower-sharing is one of the major growth drivers for the telecom industry, as it provides benefits like cost reduction and faster data rollout. The telecom tower industry has gained high prominence as an independent industry, mainly in India and the United States.
Over the years, millions of dollars have been spent on improving broadband connectivity to the rural areas. The annual data usage via wireless networks has been increasing rapidly, promoting the smartphone penetration considerably. In 2015, the US Department of Agriculture invested around USD 85 million for improving the internet connectivity in the rural areas of the country. However, government initiatives are not the only factors responsible for promoting internet connectivity in the rural areas.
The broadband adoption can help improve the economy in rural areas by increasing income, creating jobs, and by lowering unemployment rates. However technology keeps improving, enabling existing wiring to carry more and more data. Alternative techniques are being used to promote broadband in rural areas. For instance, broadband via mobile phone technology or via satellite. Though via satellite is an expensive alternative, it stands as one of the dependable sources of broadband for people staying in rural areas.
Despite regular investments from the governments, many rural areas around the world lack access to high-speed internet services. With the introduction of next-generation technologies, such as the Internet of Things, and advanced connectivity spectrums, like 5G, the global telecom tower market is expected to have an increase in demand over the next few years.
The environmental impacts of telecom towers have always been a major concern. Radiation from mobile towers has always been an issue, which is recognized as an unseen and subtle pollutant that may be affecting life forms in multiple ways.
Installation across a few regions has been stopped, considering the local public’s fear of the environmental damage that the presence of the mobile towers may cause in the neighborhood. For instance, the residents of Clear Lake Riviera, California, have cited fire danger as their primary concern toward the installation of a telecom tower. Telecom operators like Verizon and AT&T are finding a need for the tower in the region, however, the concerns of the public has been delaying the process. The tower is ready for set up by December 2018, after the feasibility tests conducted by Horizon Tower, a prominent telecom infrastructure provider. Although in the above cited instance, installation got a nod, the impact of the environmental concerns cited by the public in the setting up of the towers has been evident.
Scope of the Report
The increasing data usage by consumers has led to a competitive telecom landscape across regions. With tower sharing becoming increasingly popular among the MNOs, the tower operators have been able to reach operational efficiencies. Independent tower companies owned around 70% of the total 4.10 million towers around the world (as of 2017). China has the highest number of telecom towers in the world, owned by the state-run China Tower Corporation. They have around 1,968,000 towers and it was estimated that they are leasing over 550,000 towers.
Key Market Trends
Lattice Tower is expected to register a Significant Growth
Lattice telecom towers are mostly three-legged towers, with tubular leg elements and tubular bracing members. They are used explicitly in case of heavy loads, which makes them suitable for central communication hubs and MW backbone sites in hurricane zones.The primary purpose of setting up a lattice telecom tower in a telecom network is to support more than one antenna for communication purposes. These towers also support the load of supporting apparatus used in communication networks.
Lattice telecom towers find their primary applications in radars, video surveillance equipment, and GSM/CDMA equipment. They can be used as electricity transmission towers, radio towers, or as an observation tower.
The weight of the lattice tower is spread over a greater area, which reduces the pressure on the foundation and the ground. The modules of a lattice telecom tower can be assembled easily and does not require heavy equipment and cranes, which further optimizes the cost spending of vendors.The truss action and larger base dimensions of this infrastructure help resist the applied loads more effectively, leading to a lighter structural design. Also, wind loads are reduced due to the lattice topology.
North America is Expected to Hold Major Share
The North American region has been witnessing a significant shift, with the majority of towers being increasingly transferred from MNOs to independent tower companies. Owing to supporting initiatives by the governments, the region is expected to continually strengthen its position in the global market. For instance, the US Department of State’s Global Connect Initiative (GCI) aims to bring an additional 1.5 billion people online by 2020, thus creating a demand for more connectivity and network infrastructure.
Moreover, aggregate annual wireless capital expenditure in the United States was valued at USD 30 billion, which is expected to augment the market’s growth. In 2017, the number of mobile phone users in the United States is expected to reach about 266 million, with mobile internet penetration of about 237.2 million. Mobile internet penetration is expected to cross 275 million by 2023. Increasing wireless data usage continues to compel wireless service providers to improve their networks’ quality, and make incremental investments on the coverage and capacity of their networks.
Subscriber adoption of advanced wireless data applications, particularly mobile video, advanced devices, and densification of advanced networks by wireless service providers, to satisfy the growing demand for high-bandwidth wireless data, are driving the increased deployment of towers in the region.
Competitive Landscape
The Telecom Tower Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on Telecom Tower Market to strengthen their product capabilities. In April 2018, Crown Castle International Corp. announced that its subsidiary, CCR S.r.l., agreed to purchase a 49% interest in RaiWay S.p.A, a subsidiary of RAI (Radiotelevisione Italiana) S.p.A., the Italian state-owned television and radio broadcaster, for approximately USD 380 million. RaiWay employs over 750 people and manages over 2,300 broadcast transmission sites across Italy, representing Italy’s largest broadcast tower network.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Connecting/Improving Connectivity To Rural Areas
4.3.2 Providing Wider Coverage And Catering To Increasing Data Needs
4.4 Market Restraints
4.4.1 Environmental Concerns About Power Supply Systems To Towers
4.4.2 Tower-sharing Between Telecom Companies
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Fuel Type
5.1.1 Renewable
5.1.2 Non-Renewable
5.2 By Type of Tower
5.2.1 Lattice Tower
5.2.2 Guyed Towers
5.2.3 Monopole Towers
5.2.4 Stealth Towers
5.3 By Installation
5.3.1 Rooftop
5.3.2 Ground Based
5.4 By Ownership
5.4.1 Operator Owned
5.4.2 Joint Venture
5.4.3 Private Owned
5.4.4 MNO Captive
5.5 Geography
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Latin America
5.5.5 Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bharti Infratel Limited
6.1.2 Helios Towers Africa
6.1.3 American Tower Corporation
6.1.4 SBA Communications Corporation
6.1.5 AT&T Inc.
6.1.6 GTL Infrastructure Ltd
6.1.7 T-Mobile Towers
6.1.8 Crown Castle International Corporation
6.1.9 China Tower Corporation
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Fuel Type
Renewable
Non-Renewable
By Type of Tower
Lattice Tower
Guyed Towers
Monopole Towers
Stealth Towers
By Installation
Rooftop
Ground Based
By Ownership
Operator Owned
Joint Venture
Private Owned
MNO Captive
Geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
HVAC Services Market – Growth, Trends, and Forecast (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The HVAC Services Market is expected to register a CAGR of over 6.1% during the forecast period 2019 – 2024. Growing construction business in major emerging economies and the growing end-user markets, like data center market, etc., are major factors driving the growth of the HVAC services market, over the forecast period. Since the service firms rely extensively on labor for their operations, the existing demand and supply gap in the labor/HVAC technicians clubbed with high-cost technicians is expected to restrain the growth of the market.
Construction activity has a positive impact on not only the HVAC equipment market, but also the service market. With increased construction activity in emerging economies, the investments on infrastructure are on the rise, in order to cater to the increasing standard of living. The Asia-Pacific region tops world growth, with an expected 6.3% increase in GDP, in 2018, according to the World Bank. China, in particular, shows strong development, leading the region in terms of growth, innovation, and major investments. Moreover, both the International Monetary Fund and the World Bank predict that strong economic growth will continue in the region, until at least 2020, which will positively impact the construction sector, as the region is witnessing major investments in construction projects.
Thus, the installation and maintenance segment of the HVAC service market, is expected to benefit, due the increasing sales of HVAC equipment, through new construction projects. With regards to constructional developments globally, according to a report by Oxford Economies, construction output is forecasted to expand by 85%, to USD 15.5 trillion worldwide, in 2030, with regions like United States., China, and India accounting for 57% of the market growth.
Thus, the installation and maintenance segment of the HVAC service market, is expected to benefit, due the increasing sales of HVAC equipment, through new construction projects. With regards to constructional developments globally, according to a report by Oxford Economies, construction output is forecasted to expand by 85%, to USD 15.5 trillion worldwide, in 2030, with regions like United States., China, and India accounting for 57% of the market growth.
The Scope of the Report
The HVAC (heating, ventilation and air conditioning) services market includes the different services provided to the end users by the OEMs and other regional players. The services primarily include installation and system integration, maintenance, and repair, etc. The end users include building contractors and owners (non-residential), home owners, retail stores, food services companies, pharmaceutical, and healthcare companies, among others. The HVAC service market has a direct correlation with the HVAC equipment market. Any changes in demand for the equipment will impact the service market positively as higher demand for new equipment leads to higher installation or retrofitting services.
Key Market Trends
Residential Segment is expected to register a Significant Growth
The demand for HVAC services in the residential sector, is primarily from Asia-Pacific, owing to the growing population, across the region, thereby leading to new installations. The demand in developed regions, like North America and Europe, is mainly from the maintenance and replacement services.
In the wake of the global financial crisis and housing market collapse, an overhang of housing in many mature economies, led to a breakdown in prices of existing homes, and stifled new residential construction spending.
Direct real estate investment, and increasing wealth and prosperity in regions such as APAC, Latin America, and the Middle East, are driven by economic growth. The increasing migration to existent and newly emerging cities, in these regions, is accelerating the demand for new homes.
The robust construction of residential buildings, by the private sector, coupled with the government initiatives, to bridge emerging countries’ housing shortages, are also acting as significant factors, for the growth of the studied market.For instance, in the Philippines, the government estimated that the country’s residential sector growth could come in at an annual average of 10.3%, in real terms, from 2018-2026.
According to data from the Housing and Urban Development Coordinating Council, the country’s social housing backlog is now at 5.6 million units. There were over 30,000 residential construction permits, issued by the end of the second quarter of 2017, 24% higher than in 2016.Recently, in 2018, rising rents across Toronto led to record-breaking sales, for multi-residential apartment buildings. The sales reached USD 1.2 billion, in the third quarter of 2018.
The United States is Expected to Hold Major Share
Growing government support, in the form of higher budget allocations, designed to increase home ownership and sustainable community development, and the increasing affordability of housing, may contribute to the ever growing residential construction sector.In 2017, the US government allocated a budget of USD 46.7 billion (an increase of 1.9% over the previous year), to support residential construction. The increasing population in the country may also contribute to the rising housing demand. The boom in the construction sector is likely to contribute to the expanding of the market for HVAC and HVAC services.
The US Department of Energy (DOE) has released new efficiency standards, for commercial HVAC units, in which carbon emissions must be reduced, by up to 60 million metric tons, by 2030. According to these standards, specialized units should be manufactured, being able to provide energy-efficiency, and sustainable heating and cooling solutions.
Increased construction activities, rapid urbanization, infrastructural reforms, and HVAC unit replacements, are some of the major factors supporting the growth of HVAC services market in the country.The DOE has invested almost USD 8 million, to replace old refrigerants, with energy efficient alternatives, which can minimize environmental threats posed by rooftop HVAC units.
Competitive Landscape
The HVAC Services Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on HVAC Services technologies to strengthen their product capabilities. In March 2018, Honeywell launched Amazon Alexa voice-ready thermostat for hotels. Honeywell’s INNCOM e7 Thermostat (e7) is the first enterprise grade environmental control and energy management solution that incorporates Amazon Alexa voice control for an effortless guest experience that includes room temperature, lighting, drapery, and amenities services.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Growing Construction Business In Major Emerging Economies
4.3.2 Growing Data Center Market
4.4 Market Restraints
4.4.1 Labor Shortage/ High Costs Of Skilled Labor
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Services
5.1.1 Maintenance and Repair
5.1.2 Installation
5.2 By Implementation Type
5.2.1 New Construction
5.2.2 Retrofit Buildings
5.3 By End User
5.3.1 Residential
5.3.2 Commercial
5.3.3 Industrial
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Rest of Asia-Pacific
5.4.4 Latin America
5.4.4.1 Brazil
5.4.4.2 Argentina
5.4.4.3 Mexico
5.4.4.4 Rest of Latin America
5.4.5 Middle East and Africa
5.4.5.1 UAE
5.4.5.2 Saudi Arabia
5.4.5.3 South Africa
5.4.5.4 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Panasonic Corporation
6.1.2 Honeywell International Inc
6.1.3 LG Electronics
6.1.4 Siemens AG
6.1.5 Electrolux Ab
6.1.6 Ingersoll-Rand PLC
6.1.7 Carrier Corporation
6.1.8 Johnson Controls Inc
6.1.9 Daikin Industries Ltd
6.1.10 Nortek Global HVAC
6.1.11 Lennox International, Inc.
6.1.12 Fuijitsu General Ltd
6.1.13 Robert Bosch GmbH
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Services
Maintenance and Repair
Installation
By Implementation Type
New Construction
Retrofit Buildings
By End User
Residential
Commercial
Industrial
Geography
North America
US
Canada
Europe
Germany
UK
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Middle East and Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East and Africa
Glucagon like Peptide 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.
Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.
In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly’s Trulicity will dominate the market during the forecast period.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.
Key Market Trends –
Constant Global Trend of High Diabetes Prevalence
The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
North America to Dominate the Market in Terms of Revenue
North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all regions.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Teva confirmed generic Victoza and announced that it had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market the generic version of Novo Nordisk’s Victoza® (liraglutide) injection, in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2 Europe
5.2.2.1 Germany (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.2 Spain (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.4 France (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3 Asia-Pacific
5.2.3.1 Japan (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.2 China (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.3 Australia (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.4 India (Value and Volume 2012-2024)
5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.5 South Korea (Value and Volume 2012-2024)
5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.6 Malaysia (Value and Volume 2012-2024)
5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.7 Indonesia (Value and Volume 2012-2024)
5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.8 Thailand (Value and Volume 2012-2024)
5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.9 Philippines (Value and Volume 2012-2024)
5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4 Latin America
5.2.4.1 Brazil (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.2 Mexico (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5 Middle East & Africa
5.2.5.1 South Africa (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.3 Oman (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.4 Egypt (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.5 Iran (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
North America
US (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Canada (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of North America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Europe
Germany (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Spain (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Italy (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
(Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
France (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
UK (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Russia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Latin America
Brazil (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Mexico (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Middle East & Africa
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)